-
公开(公告)号：US20250064930A1
公开(公告)日：2025-02-27
申请号：US18948772
申请日：2024-11-15
Applicant: Chugai Seiyaku Kabushiki Kaisha
Inventor： Daisuke Kameoka , Toru Yoshizawa , Megumi Numata , Hitoshi Sasaki , So Yamaguchi , Hiroko Murata , Naoka Hironiwa
IPC: A61K39/395 , A61K9/08 , A61K9/19 , A61K39/00 , A61K47/10 , A61K47/18 , A61K47/26 , C07K14/715 , C07K16/28
Abstract: In one non-limiting embodiment, the present disclosure relates to lyophilized formulations containing an IL-31 antagonist (for example, an anti-IL-31RA antibody) as an active ingredient, the lyophilized formulations further containing arginine and/or a salt thereof and sucrose and/or trehalose. In another non-limiting embodiment, the present disclosure relates to solution formulations containing an IL-31 antagonist as an active ingredient, the solution formulations further containing arginine and/or a salt thereof. In other non-limiting embodiments, the present disclosure relates to methods for stabilizing an antibody (for example, an anti-IL-31RA antibody) in an antibody-containing formulation, methods for suppressing antibody aggregation (aggregate formation) in an antibody-containing formulation, and methods for reducing components with charge heterogeneity in an antibody-containing formulation, the methods being characterized in that the formulation is prepared to contain arginine and/or a salt thereof, and/or sucrose and/or trehalose.
-
公开(公告)号：US20250064897A1
公开(公告)日：2025-02-27
申请号：US18236300
申请日：2023-08-21
Applicant: CMPD Licensing, LLC
Inventor： Daniel Banov , Gus Bassani , Jay Richard Ray, II
Abstract: A method of treating type-2 diabetes, chronic weight maintenance, or overindulgence conditions includes administering a pharmaceutically effective amount of a topical composition comprising a GLP-1 receptor agonist suspended in an anhydrous suspension base vehicle to an oral cavity of a subject for oral absorption therein. The topical composition is formulated to form a self-emulsifying liposome in an aqueous environment of the oral cavity.
-
公开(公告)号：US20250064828A1
公开(公告)日：2025-02-27
申请号：US18943269
申请日：2024-11-11
Applicant: ALKEM LABORATORIES LIMITED
Inventor： Akhilesh SHARMA , Babasaheb AWARE , Viraj SHAH , Amol AIWALE
Abstract: The present invention relates to a nasal pharmaceutical composition comprising alcaftadine or a pharmaceutically acceptable salt and optionally one or more pharmaceutically acceptable excipients, methods of treating allergic rhinitis, allergic rhino-conjunctivitis, or symptoms thereof (such as nasal congestion) with the nasal pharmaceutical composition, and methods of preparing it.
-
公开(公告)号：US20250064826A1
公开(公告)日：2025-02-27
申请号：US18943165
申请日：2024-11-11
Applicant: ALKEM LABORATORIES LIMITED
Inventor： Akhilesh SHARMA , Babasaheb AWARE , Viraj SHAH , Amol AIWALE
Abstract: The present invention relates to a nasal pharmaceutical composition comprising alcaftadine or a pharmaceutically acceptable salt and optionally one or more pharmaceutically acceptable excipients, methods of treating allergic rhinitis, allergic rhino-conjunctivitis, or symptoms thereof (such as nasal congestion) with the nasal pharmaceutical composition, and methods of preparing it.
-
公开(公告)号：US20250064797A1
公开(公告)日：2025-02-27
申请号：US18942141
申请日：2024-11-08
Applicant: ANTECIP BIOVENTURES II LLC
Inventor： Herriot Tabuteau
IPC: A61K31/485 , A61K9/00 , A61K31/137 , A61K47/02 , A61K47/10 , A61K47/12 , A61K47/14 , A61K47/18 , A61K47/20 , A61K47/32 , A61K47/38
Abstract: This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg of bupropion hydrochloride, or a molar equivalent amount of a free base form or another salt form of bupropion; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of a free base form or another salt form of dextromethorphan in certain patient populations, such as patients having moderate renal impairment, patients receiving a concomitant strong CYP2D6 inhibitor, patients who are known CYP2D6 poor metabolizers, those in need of an NMDA antagonist that does not cause dissociation, and those at risk of QT prolongation.
-
Patent Agency Ranking
6.发明授权公开(公告)号：US12233133B2
公开(公告)日：2025-02-25
申请号：US18517529
申请日：2023-11-22
Applicant: Oculis Operations Sàrl
Inventor： Thorsteinn Loftsson , Zoltán Fülöp
IPC: A61K47/69 , A61K9/00 , A61K9/08 , A61K9/10 , A61K9/14 , A61K9/50 , A61K9/51 , A61K31/4184 , A61K31/573 , A61K47/02 , A61K47/10 , A61K47/12 , A61K47/18 , A61K47/34 , A61K47/38 , A61P27/02 , A61K47/40
Abstract: The present disclosure relates to ophthalmic compositions containing solid complexes of active pharmaceutical ingredient and cyclodextrin, to their method of preparation and their uses. The compositions can include an active agent drug/cyclodextrin complex substantially dissolved in an aqueous eye drop vehicle. The ophthalmic composition is generally in the form of a microsuspension including an active agent complex having a diameter of less than about 100 μm.
-
7.发明授权公开(公告)号：US12233112B2
公开(公告)日：2025-02-25
申请号：US18444471
申请日：2024-02-16
Applicant: i2O Therapeutics, Inc.
Inventor： Tyler Brown , Kelly Ibsen
IPC: A61K39/395 , A61K9/08 , A61K31/14 , A61K38/26 , A61K47/12 , A61K47/18 , A61K47/54 , A61K47/68 , C07K14/575 , C07K14/605 , C07K16/24 , A61K38/00
Abstract: Provided herein are compounds having the structure of Formula Ia, wherein the compounds comprise a therapeutic agent having the configuration of [diacid]-[linker]-[an amylin analog], in which the amylin analog has the amino acid sequence of SEQ ID NO: 20, with a proviso that the amino acid sequence comprises one or more of the following amino acid substitutions: N14E, V17R, Y37P, F15E, L16E, V17E, or any combination thereof, and the compounds have an anion: cation molar ratio of from about 1:1 to about 1:3, and methods of using thereof for the treatment of metabolic diseases or disorders, including type 1 diabetes, type 2 diabetes, obesity, overweight, and nonalcoholic steatohepatitis, and for reducing weight in a subject in need thereof.
-
公开(公告)号：US12233110B2
公开(公告)日：2025-02-25
申请号：US18444443
申请日：2024-02-16
Applicant: i20 Therapeutics, Inc.
Inventor： Tyler Brown , Kelly Ibsen
IPC: A61K38/22 , A61K9/08 , A61K31/14 , A61K38/26 , A61K47/12 , A61K47/18 , A61K47/54 , A61K47/68 , C07K14/575 , C07K14/605 , C07K16/24 , A61K38/00
Abstract: Provided herein are compounds having the structure of Formula I, wherein the compounds comprises a therapeutic agent having the sequence of SEQ ID NO: 35, and the compounds have an anion:cation molar ratio of from about 1:1 to about 1:7, and methods of using thereof for the treatment of metabolic diseases or disorders, including type 1 diabetes, type 2 diabetes, obesity, overweight, and nonalcoholic steatohepatitis, and for reducing weight in a subject in need thereof.
-
公开(公告)号：US20250057818A1
公开(公告)日：2025-02-20
申请号：US18807584
申请日：2024-08-16
Applicant: VETERINARY PHARMACY CORPORATION
Abstract: A formulation of a single phase solution, including aminopenicillin, a stabilizing agent, and water. The aminopenicillin in the solution has a potency of 87% or higher at 24 hours of storage at room temperature. A formulation of a single phase solution, including amoxicillin, ampicillin, and/or a combination thereof, a stabilizing agent, and water. The amoxicillin, ampicillin, and/or a combination thereof in the solution has a potency of 87% or higher at 24 hours of storage at room temperature. A formulation of a single phase solution, including amoxicillin, a stabilizing agent, and water. The amoxicillin in the solution has a potency of 87% or higher at 24 hours of storage at room temperature. A formulation of a single phase solution, including ampicillin, a stabilizing agent, and water.
-
公开(公告)号：US12226457B2
公开(公告)日：2025-02-18
申请号：US16866764
申请日：2020-05-05
Applicant: Ascendis Pharma Endocrinology Division A/S
Inventor： Grethe Nørskov Rasmussen , Susanne Kindermann , Harald Rau , Thomas Wegge
IPC: A61K38/27 , A61K9/00 , A61K9/08 , A61K9/19 , A61K45/06 , A61K47/10 , A61K47/12 , A61K47/18 , A61K47/26 , A61K47/60 , A61M5/19
Abstract: The present invention relates to dry compositions of rhGH polymer prodrug containing a lyoprotectant and, optionally, one or more than one excipient. Such compositions are stable for at least 1 year, when stored at 2-8° C. The invention further relates to methods of manufacturing said compositions, containers comprising such composition as well as a kit of parts.
-
-
-
-
-
-
-
-
-
Search Results
6762
records
(took 0.048 seconds)
